Bharat Parenterals' record carries a clean audit history, but the consolidated picture is where the strain shows: the group reported a consolidated loss of ₹29.99 crore against a standalone profit of ₹9.69 crore, and the gap sits in subsidiaries that are absorbing shareholder funds. The major flags cluster around related-party loans, acquisition accounting, and a governance exception that has persisted for years.
Key findings
- Shareholder funds flow into a loss-making subsidiary via unsecured loans
Major- Innoxel Lifesciences, a 55.89%-owned subsidiary, lost ₹67.93 crore on ₹27.98 crore of turnover last year, yet the company seeks approval for unsecured loans up to ₹75 crore, 268% of that subsidiary's turnover and 22% of consolidated turnover. CARO disclosures show ₹61.92 crore already outstanding as of FY2024-25, with loans granted every year since FY2021-22. The auditor disclosed that preferential-allotment funds were received with the understanding they would be invested directly into Innoxel. - A ₹51.98 crore acquisition booked goodwill against negative net assets
Major- Bharat Parenterals acquired Varenyam Healthcare on 31 Oct 2024 for ₹51.98 crore via share swap, booking goodwill of approximately ₹51.98 crore against fair value of identifiable net assets of ₹(11.80) lakh. In its first two months, the acquiree contributed ₹18.30 lakh revenue and a ₹(26.69) lakh loss. - Repeated share-swap acquisitions and a persistent governance gap in the material subsidiary
Major- The Varenyam Healthcare deal is one of several acquisitions via share swap and preferential allotment where consideration far exceeded net assets. The corporate governance certificate for FY2025-26, dated August 5, 2026, again flags the absence of an independent director in the material subsidiary, the same exception certified in FY2022-23. The company states it has no material subsidiary, while its own compliance certificate references one. - Reported profit rests on aggressive accounting choices while the group posts a loss
Major- The company did not recognise deferred tax assets on brought-forward losses, citing "no reasonable certainty of income". Investment property fair values were set using government registration rates, not valuations, in every year from FY2019-20 through FY2024-25. Consolidated PAT was ₹-29.99 crore versus standalone PAT of ₹9.69 crore, a divergence at subsidiaries. - Operating cash flow is erratic, and a ₹300 crore pre-revenue facility will consume capital for years
Major- Standalone CFO/PAT swung from -1.40x in FY26 to 0.62x in FY25, and cumulative CFO of ₹93 crore covered only 50% of cumulative EBITDA of ₹187 crore over ten years. Consolidated ROCE was -1.90% in FY26 and -4.11% in FY25. The board recommended a ₹1.00 dividend for FY2026, while Varenyam Biolifesciences' Savli facility capex was raised to approximately ₹300 crore, with commissioning targeted for September 2027 and first commercial supply in Q4 FY29. - Reported debt understates the encumbrance of assets and contingent exposure
Major- Substantially all movable and immovable property, current assets, and mutual fund investments are pledged or hypothecated to lenders, with promoter guarantees on nearly every facility. Consolidated borrowings fell to ₹146.1 crore from ₹180.2 crore, but CARO notes bank returns were not in agreement with books of account. - Statutory auditor resigned after a refused fee increase; cost auditor also resigned mid-term
Major- CNK & Associates resigned effective August 10, 2024, after the Audit Committee declined its fee-increase request, stating the current remuneration would not be commensurate with audit effort. Replacement Shah Mehta & Bakshi was appointed at a fee "significantly lesser" than CNK's proposal. Cost auditor CMA Minal Sonaje resigned effective November 23, 2021. - Promoter-family control is concentrated, with one promoter's votes invalidated in his own reappointment
Major- In the December 2024 postal ballot for MD Bharatkumar Desai's reappointment, the scrutinizer recorded 741,515 invalid votes from him, noting his votes were "not considered". Promoter and promoter group shareholding was 67.17% as of March 31, 2026, with zero pledge. The FY2022-23 AGM notice disclosed that a prior resolution erroneously stated related-party remuneration as ₹20 crore, later rectified to ₹2 crore.
What to watch
- Shareholder vote on ₹75 crore Innoxel loans. The 33rd AGM notice dated 27 August 2026 seeks approval for unsecured loans up to ₹75 crore to Innoxel for FY2026-27 and FY2027-28.
- Savli facility commissioning. Targeted for September 2027, with first regulatory filing in Q1 FY29 and first commercial supply in Q4 FY29.
- ₹66.86 crore guarantee resolution. The guarantee given to Innoxel, first disclosed as at 31 March 2024, was revoked during FY2024-25 with no outstanding obligation.
- FY2026 dividend payment. ₹1.00 per share payable on or before October 19, 2026.
- Tax disputes. Income Tax dispute of ₹52.69 lakh for FY2014-15 pending before CIT Appeal, and Service Tax dispute of ₹9.7 lakh pending before CESTAT, both as at 31 March 2024.
Bottom line: This is a disclosed and shareholder-approved record, but the disclosures themselves carry the risk. The core tension is structural: standalone profit of ₹10 crore versus a consolidated loss of ₹30 crore, with the gap funded by unsecured loans to a loss-making subsidiary and acquisitions that booked large goodwill against negative net assets. The character of the risk is capital allocation, shareholder funds moving into entities with no demonstrated return, compounded by a governance exception that has persisted for years. Watch the Innoxel vote, the Savli facility's commissioning, and whether the ₹75 crore facility gets a repayment schedule.